Isofol Medical
Clinical-stage biotech developing a folate-based therapy to enhance cancer treatments.
ISOFOL | ST
Overview
Corporate Details
- ISIN(s):
- SE0009581051
- LEI:
- 549300MCXYAHG7VBHX75
- Country:
- Sweden
- Address:
- C/O Biotech Center, Arvid Wallgrens, 413 46 Göteborg
- Website:
- https://isofolmedical.com/
Description
Isofol Medical is a clinical-stage biotechnology company dedicated to improving treatments for severe forms of cancer. The company's primary focus is the development of its lead drug candidate, arfolitixorin. This next-generation, folate-based therapy is designed to enhance the efficacy of standard cancer treatments, such as chemotherapy. Arfolitixorin is the active metabolite of commonly used folate-based drugs, potentially offering a therapeutic benefit to a broader patient population by bypassing complex metabolic activation steps. The company's goal is to help more patients respond better to their treatment, thereby improving their prognosis.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-03-20 13:10 | English | 35.4 KB | |||
| 2024-03-19 10:37 |
Isofols japanska partner Solasia har beslutat att intensifiera sitt engagemang …
|
Swedish | 68.3 KB | ||
| 2024-03-19 10:37 |
Isofol’s Japanese partner Solasia intensifies its commitment to the clinical de…
|
English | 68.2 KB | ||
| 2024-03-19 07:30 |
Isofol presents a clinical development plan for arfolitixorin
|
English | 70.4 KB | ||
| 2024-02-20 08:00 | Swedish | 494.1 KB | |||
| 2024-02-20 08:00 | Swedish | 494.1 KB | |||
| 2024-02-14 12:40 |
Styrelsen i Isofol inleder planeringen av kliniska studier och kommer att annon…
|
Swedish | 71.2 KB | ||
| 2024-02-14 12:40 |
Isofol’s Board of Directors decides to initiate the planning of clinical studie…
|
English | 83.0 KB | ||
| 2024-01-10 20:30 |
Isofol appoints Magnus Hurst as new Chief Financial Officer
|
English | 80.8 KB | ||
| 2024-01-10 20:30 |
Isofol utser Magnus Hurst till ny Chief Financial Officer
|
Swedish | 61.0 KB | ||
| 2024-01-09 08:40 |
Isofol utser Petter Segelman Lindqvist till ny verkställande direktör
|
Swedish | 65.9 KB | ||
| 2024-01-09 08:40 |
Isofol appoints Petter Segelman Lindqvist as new CEO
|
English | 111.2 KB | ||
| 2024-01-04 16:40 |
Kommuniké från extra bolagsstämma i Isofol Medical AB (publ) den 4 januari 2024
|
Swedish | 60.0 KB | ||
| 2024-01-04 16:40 |
Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on…
|
English | 81.0 KB | ||
| 2023-12-28 19:30 |
Isofol presenterar ytterligare resultat från laboratorietester med arfolitixori…
|
Swedish | 66.8 KB |
Automate Your Workflow. Get a real-time feed of all Isofol Medical filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Isofol Medical
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Isofol Medical via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-11 | Magnus Hurst | Other | Buy | 35,000 | 24,150.00 SEK |
| 2022-09-12 | AB Windar | Other | Buy | 500,000 | 305,000.00 SEK |
| 2021-12-09 | Tony Gustavsson | Other | Sell | 58,767 | 858.00 SEK |
| 2021-12-09 | Tony Gustavsson | Other | Sell | 58,767 | 152.79 SEK |
| 2021-06-14 | HealthCom GmbH | Other | Buy | 233,336 | 1,493,350.40 SEK |
| 2021-06-10 | Gustaf Albèrt | Other | Other | 15,153 | 96,979.20 SEK |
| 2020-11-23 | Tony Gustavsson | Other | Buy | 58,767 | 43,487.58 SEK |
| 2020-11-23 | Tony Gustavsson | Other | Buy | 58,767 | 29,971.17 SEK |
| 2020-11-16 | Sven Eriksson | Other | Sell | 58,767 | 43,487.58 SEK |
| 2020-11-16 | Sven Eriksson | Other | Sell | 58,767 | 29,971.17 SEK |
Peer Companies
